Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

GUTS

Fractyl Health Inc.

Oct 08 • 04:00PM ET

2.39

Dollar change +0.10
Percentage change 4.37	%

Healthcare • Biotechnology • USA • NASD

Held by: IWM VTI IWO VXF IWN IWC VTWO RSSL VTWG URTY

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-6.10	Insider Own	58.52%	Shs Outstand	47.93M	Perf Week	3.69%
Market Cap	114.55M	Forward P/E	-	EPS next Y	-2.48	Insider Trans	-0.23%	Shs Float	19.88M	Perf Month	-26.23%
Income	-65.88M	PEG	-	EPS next Q	-0.50	Inst Own	30.00%	Short Float	5.82%	Perf Quarter	-46.53%
Sales	0.12M	P/S	954.61	EPS this Y	96.46%	Inst Trans	-3.15%	Short Ratio	3.25	Perf Half Y	-67.79%
Book/sh	1.48	P/B	1.62	EPS next Y	-54.83%	ROA	-	Short Interest	1.16M	Perf Year	-
Cash/sh	2.14	P/C	1.11	EPS next 5Y	-	ROE	-	52W Range	1.74 - 14.50	Perf YTD	-81.40%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-126.07%	ROI	-51.83%	52W High	-83.52%	Beta	-
Dividend TTM	-	Quick Ratio	7.46	Sales past 5Y	0.00%	Gross Margin	-267.23%	52W Low	37.36%	ATR (14)	0.22
Dividend Ex-Date	-	Current Ratio	7.46	EPS Y/Y TTM	-	Oper. Margin	-59984.03%	RSI (14)	39.59	Volatility	6.64% 8.17%
Employees	-	Debt/Eq	0.87	Sales Y/Y TTM	-	Profit Margin	-55357.98%	Recom	1.00	Target Price	15.50
Option/Short	No / Yes	LT Debt/Eq	0.80	EPS Q/Q	-6.55%	Payout	-	Rel Volume	0.60	Prev Close	2.29
Sales Surprise	-	EPS Surprise	39.13%	Sales Q/Q	760.00%	Earnings	Aug 14 AMC	Avg Volume	356.39K	Price	2.39
SMA20	-6.33%	SMA50	-12.18%	SMA200	-57.02%	Trades		Volume	213,647	Change	4.37%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-28-24	Initiated	Evercore ISI	Outperform
Feb-27-24	Initiated	Morgan Stanley	Overweight	$18
Feb-27-24	Initiated	BofA Securities	Buy	$26

Sep-24-24 07:00AM	Fractyl Health to Present at Chardan's 8th Annual Genetic Medicines Conference (GlobeNewswire)
Sep-03-24 07:00AM	Fractyl Health to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-14-24 04:05PM	Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) +5.38%
Aug-12-24 10:53AM	Rising diabetes rates spur growth in weight management solutions (Medical Device Network) +14.61%
Aug-08-24 12:13PM	Fractyl Health touts positive year-long weight loss results for Revita device (Clinical Trials Arena) -6.19%
08:00AM	Loading…
08:00AM	Fractyl Health Announces Clinical Results from German Real-World Registry Showing Meaningful and Sustained Weight Loss for at Least One Year After a Single Revita Endoscopic Procedure (GlobeNewswire)
Aug-07-24 07:00AM	Fractyl Health to Report Second Quarter 2024 Financial Results and Provide Business Updates on August 14, 2024 (GlobeNewswire) -9.77%
Jul-30-24 07:00AM	Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs (GlobeNewswire)
Jun-25-24 09:02AM	FDA expands Fractyl endoscopy trial to include untreated diabetes patients (Medical Device Network) -9.22%
07:00AM	Fractyl Health to Present at Piper Sandler 2nd Annual Virtual Obesity Day (GlobeNewswire)
Jun-24-24 06:00AM	Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates (GlobeNewswire) +5.76%
Jun-23-24 01:30PM	Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva Single-Administration GLP-1 Pancreatic Gene Therapy in President's Select Oral Presentation at the American Diabetes Association's 84th Scientific Sessions (GlobeNewswire)
May-29-24 07:00AM	Fractyl Health to Present New Preclinical Obesity Data from Rejuva Platform at the American Diabetes Association's 84th Scientific Sessions (GlobeNewswire)
May-20-24 06:00AM	Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva at Digestive Disease Week 2024 (GlobeNewswire)
May-13-24 08:56PM	GUTS Stock Earnings: Fractyl Health Beats EPS for Q1 2024 (InvestorPlace) +8.52%
04:00PM	Loading…
04:00PM	Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
11:41AM	Fractyl Health Says New Revita Data Show Sustained Weight Loss, Glucose Control in Type 2 Diabetes (MT Newswires)
06:00AM	Fractyl Health Presents Clinical Update on Revita German Real-World Registry for Patients With Advanced Type 2 Diabetes (T2D) (GlobeNewswire)
May-08-24 06:00AM	Fractyl Health to Present at BofA Securities 2024 Health Care Conference (GlobeNewswire)
May-07-24 06:00AM	Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024 (GlobeNewswire)
Apr-30-24 08:38AM	Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting (GlobeNewswire)
Apr-17-24 03:10PM	The 3 Most Volatile Stocks for Short-Term Traders: April 2024 (InvestorPlace)
Apr-02-24 08:00AM	Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes (GlobeNewswire) -9.53%
Apr-01-24 07:00AM	Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
06:00AM	Fractyl Health Receives FDA IDE Approval for the Revita Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs (GlobeNewswire)
Mar-12-24 02:06PM	UPDATE -- Fractyl Health Announces New Results From Its Rejuva Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity (GlobeNewswire) -10.34%
08:38AM	Fractyl Health Announces New Results From Its Rejuva Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity (GlobeNewswire)
Mar-03-24 01:13PM	Analysts Bet Big on These Beaten-Down IPO Stocks (TipRanks)
Feb-20-24 08:38AM	Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita Pivotal Clinical Trials (GlobeNewswire)
Feb-01-24 08:08PM	Fractyl Health Announces Pricing of Initial Public Offering (GlobeNewswire)

Fractyl Health, Inc. is a metabolic therapeutics company. It develops medical device solutions for the treatment of metabolic diseases, which includes type 2 diabetes and obesity. The company was founded by Harith Rajagopalan and Jay D. Caplan on August 30, 2010 and is headquartered in Burlington, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Caplan Jay David	President, Chief Product Off.	Sep 12 '24	Option Exercise	1.70	95,484	162,323	95,484	Sep 13 06:39 PM
Caplan Jay David	President, Chief Product Off.	Sep 12 '24	Sale	2.90	65,000	188,474	30,484	Sep 13 06:39 PM
JAY D CAPLAN	Officer	Sep 12 '24	Proposed Sale	2.85	65,000	185,213		Sep 12 04:44 PM
Royan Ajay	Director	Feb 06 '24	Buy	15.00	333,333	4,999,995	1,251,900	Feb 08 04:37 PM
Mithril LP	10% Owner	Feb 06 '24	Buy	15.00	333,333	4,999,995	1,251,900	Feb 08 04:35 PM
Elia Marc	Director	Feb 06 '24	Buy	15.00	466,666	6,999,990	1,856,117	Feb 08 04:32 PM
CVF, LLC	10% Owner	Feb 06 '24	Buy	15.00	333,333	4,999,995	4,673,870	Feb 06 08:39 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GUTS

Fractyl Health Inc.

Upgrade your FINVIZ experience